ATXI Share Price Performance
US$0.75
-1.15 (-60.63%)
Price US$0.75
Share Pricen/a
Avenue Therapeutics, Inc. Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 2 Fair Values set on narratives written by author
ATXI Community Narratives
There are no narratives available yet.
There are no community narratives available.
Trending Discussion
Recently Updated Narratives
No recently updated narratives available.
Snowflake Analysis
Avenue Therapeutics, Inc. Key Details
Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
n/a
- -1.18
- 100.00%
- -266.67%
- 0%
About ATXI
- Founded
- 2015
- Employees
- 2
- CEO
- WebsiteView website
Avenue Therapeutics, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. The company product candidates include AJ201, which is in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; and intravenous tramadol for the treatment of post-operative acute pain. It also develops BAER-101 for the treatment of epilepsy and panic disorders. The company was incorporated in 2015 and is headquartered in Bay Harbor Islands, Florida. Avenue Therapeutics, Inc. is a subsidiary of Fortress Biotech, Inc.
